Action A086900 MEDY-TOX INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Medy-Tox Inc.

Actions

A086900

KR7086900008

Cours en clôture Korea S.E.
Autres places de cotation
 00:00:00 07/06/2024 		Varia. 5j. Varia. 1 janv.
138 900 KRW -1,21 % Graphique intraday de Medy-Tox Inc. +6,36 % -42,37 %
16/05 Medy-Tox Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
21/03 Medy-Tox Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing
Medy Tox Establishes Subsidiary Luvantas in California
Medytox, Inc. Announces the Formation of Luvantas Subsidiary
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.
Medy-Tox Inc. authorizes a Buyback Plan.
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action A086900
  4. Actualités Medy-Tox Inc.
  5. Autres langues